share_log

Takeda's Angioedema Drug Shows Promising Action Against COVID-19 Infection

Takeda's Angioedema Drug Shows Promising Action Against COVID-19 Infection

武田公司的血管水肿药物显示出对抗新冠肺炎感染的良好效果
Benzinga Real-time News ·  2022/03/08 08:56
  • Takeda Pharmaceutical Co Ltd's (NYSE:TAK) Firazyr (icatibant), used to treat a blood vessel condition called angioedema, has shown promise as a treatment for COVID-19 in lab experiments.
  • Icatibant blocks a protein called bradykinin receptor b2 in the so-called kinin system. 
  • The ACE2 protein regulates the protein on cell surfaces, which the coronavirus uses as a gateway for infection. 
  • In lab testing, repeated dosing of icatibant did not stop coronavirus infection completely but reduced the severity of infection. 
  • While a low concentration of 1 nM B2R-antagonist was sufficient to reduce viral RNA in primary bronchial epithelial cells when cells were treated pre-infection, 100 nM B2R-antagonist was required to this effect when cells were treated post-infection. 
  • In addition, the significant reduction in virus load as determined by PCR tapered off after 96 hours. 
  • But on the other hand, the B2R-antagonist icatibant used in this study has a short half-life in the human body.
  • The researchers noted that pharmacological tolerance to interference at receptor level might explain why the effect reached significance after 6 hours but did not persist. 
  • Therefore, it may be required to administer higher doses of the B2R-antagonist to COVID-19 patients a few times per day to inhibit viral replication in the long term.
  • Price Action: TAK shares are down 1.62% at $14.58 during the premarket session on the last check Tuesday.
  • 武田药品工业株式会社(纽约证券交易所股票代码：TAK)Firazyr(Icatibant)用于治疗一种名为血管水肿的血管疾病，在实验室实验中显示出作为新冠肺炎治疗药物的前景。
  • Icatibant阻断了所谓激肽系统中一种名为缓激肽受体b2的蛋白质。
  • ACE2蛋白调节细胞表面的蛋白质，冠状病毒将其用作感染的门户。
  • 在实验室检测中，反复服用icatibant并没有完全阻止冠状病毒的感染，但减轻了感染的严重程度。
  • 当细胞感染前处理时，低浓度的1 nM B2R拮抗剂足以减少原代支气管上皮细胞中的病毒RNA，而感染后处理细胞时则需要100 nM的B2R拮抗剂。
  • 此外，通过PCR检测病毒载量的显著降低在96小时后逐渐消失。
  • 但另一方面，本研究中使用的B2R拮抗剂在人体内的半衰期很短。
  • 研究人员指出，受体水平对干扰的药理学耐受性可能解释了为什么这种效果在6小时后达到显著水平，但并不持续。
  • 因此，可能需要每天给新冠肺炎患者服用更大剂量的B2R拮抗剂几次，以长期抑制病毒复制。
  • 价格行动：周二盘前交易时段，德意志银行股价下跌1.62%，至14.58美元。
声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发